Whole-brain radiotherapy for brain metastases: Evolution or revolution?

Paul D. Brown*, Manmeet S. Ahluwalia, Osaama H. Khan, Anthony L. Asher, Jeffrey S. Wefel, Vinai Gondi

*Corresponding author for this work

Research output: Contribution to journalReview article

35 Scopus citations

Abstract

An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brainmetastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use ofWBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.

Original languageEnglish (US)
Pages (from-to)483-491
Number of pages9
JournalJournal of Clinical Oncology
Volume36
Issue number5
DOIs
StatePublished - Feb 10 2018

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this